Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Galmed Pharmaceuticals Ltd GLMD posted results of the Phase 1 trial of Amilo-5MER in healthy volunteers.

  • Amilo-5MER is a synthetic peptide consisting of 5 amino acids that significantly reduces symptoms and histopathological hallmarks of Inflammatory bowel disease (IBD) in animal models (TNBS, DSS). 
  • TNBS and DSS are well-established and widely recognized models of acute colitis. 
  • Related: Galmed's NASH Candidate Shows Clinically Significant Effect On Fibrosis Improvement.
  • Amilo-5MER also showed anti-inflammatory effects in animal models of multiple sclerosis and rheumatoid arthritis. 
  • Amilo-5MER binds with high affinity to pro-inflammatory amyloid proteins, preventing polymerization of Serum Amyloid A (SAA) monomers and thereby interfering with SAA-induced immune cell activation.  
  • All doses of Amilo-5MER were well tolerated with no clinically significant adverse events, and none considered related to the investigational product. 
  • The company plans to submit an IND for mild to moderate ulcerative colitis in 2022.
  • Price Action: GLMD shares are down 10.9% at $1.68 during the premarket session on Monday's last check.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPhase 1 Trialulcerative colitis
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!